**UNITED STATES**
**SECURITIES AND EXCHANGE COMMISSION**
**Washington, D.C. 20549**

# FORM 8-K

**CURRENT REPORT**
**PURSUANT TO SECTION 13 OR 15(d) OF THE**
**SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported): October 27, 2008**

# ADVENTRX Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

| **Delaware** | **001-32157** | **84-1318182** |
|---|---|---|
| (State or Other Jurisdiction of Incorporation) | (Commission File No.) | (IRS Employer Identification No.) |

**6725 Mesa Ridge Road, Suite 100**
**San Diego, CA 92121**
(Address of Principal Executive Offices and Zip Code)

**N/A**
(Former name or former address if changed since last report)

Registrant's telephone number, including area code: **(858) 552-0866**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On October 27, 2008, ADVENTRX Pharmaceuticals, Inc. ("ADVENTRX") revised its corporate presentation. Certain portions of the revised presentation are reflected in the slides attached as Exhibit 99.1 and are incorporated herein by reference.

Forward Looking Statements

ADVENTRX cautions you that statements information included in this report and the slides attached hereto as Exhibit 99.1 that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that ADVENTRX will be unable to raise sufficient capital to fund the projects necessary to meet its goals; the risk that preclinical results are not indicative of the success of subsequent clinical trials and the results of pending clinical trials; the risk the FDA determines ADVENTRX's product candidates are not bioequivalent to the applicable reference product; difficulties or delays in developing, manufacturing, obtaining regulatory approval for and marketing ADVENTRX's product candidates; the potential for regulatory authorities to require additional preclinical work or other clinical requirements to support regulatory filings; the scope and validity of patent protection for ADVENTRX's product candidates; patent and non-patent exclusivity covering Navelbine® and Taxotere®; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to update any forward-looking statement included in this report or the slides attached hereto as Exhibit 99.1 to reflect events or circumstances arising after the date on which it was made. This caution is made under the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

The list of exhibits called for by this Item is incorporated by reference to the Exhibit Index filed with this report.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

**ADVENTRX Pharmaceuticals, Inc.**

Dated: October 27, 2008

By: /s/ Patrick L. Keran
Name: Patrick L. Keran
Title: Vice President, Legal

EXHIBIT INDEX

99.1 Select presentation slides

# ANX-530 Market Research & Forecast

## *Third Party Conjoint Study of 70 U.S.-Based Medical Oncologists*

### *Oncologist Preference for ANX-530 at 10x Generic Pricing Prior to J-code Assignment*

***Share preference unaffected by reimbursement code even at 10x generic pricing***

| NSCLC Preference Share | | | |
|---|---|---|---|
| **Therapy** | Misc. J-code **WAC +6%** | Unique J-code **ASP+6%, 0% disc.** | **Δ** |
| **ANX-530** | **74.6% ±9.3** | **70.9% ±9.3** | **+1.3%** |
| **Vinorelbine** | **25.4% ±9.3** | **29.1% ±9.3** | **-1.3%** |

*Conjoint derived (N = 70)*



# ANX-514 Market Research & Forecasting

## *Oncologist's Willingness to Switch Patients to ANX-514 Prior to J-code Assignment*

*"Upon launch of ANX-514, and prior to assignment of the product J-code, you estimate that you would begin using ANX-514 instead of Taxotere for what portion of your planned docetaxel patients?"*




*ADVENTRX ANX-514 Web-based Survey of 100 Oncologists: Oct. 2008*

# ANX-514 Market Research & Forecasting

## *Oncologist's Willingness to Remain with Premium-Priced ANX-514 <u>After</u> Generic Availability*

*"In 2012, once generic Taxotere is available, assume that for a year there is a large spread between the quickly-falling acquisition price of generic Taxotere, being driven down by competing generic manufacturers and the payor reimbursement rates due to the lag time (assume that ANX-514 pricing and reimbursement remains the same with no impact due to generics), what would your planned use of ANX-514 be?"*




*ADVENTRX ANX-514 Web-based Survey of 100 Oncologists: Oct. 2008*

# Near Term Regulatory Milestones

## Q1 2009

Complete enrollment in BE study of ANX-514 (docetaxel emulsion)

## Q2 2009

Submit New Drug Application for ANX-530 (vinorelbine emulsion)
Announce results from BE study of ANX-514 (docetaxel emulsion)

## Q3 2009

Submit New Drug Application for ANX-514 (docetaxel emulsion)

# ADVENTRX Team

**Mark N. K. Bagnall, Executive Vice President & Chief Financial Officer**

Metabolex Inc.; Metrika, Inc.; Progenitor, Inc.; Somatix Therapy Corp.; Hana Biologics, Inc.

**Brian M. Culley, M.S., M.B.A., Chief Business Officer & SVP Business Development**

Immusol; UCSD Technology Transfer and Intellectual Property Dept.; Neurocrine Biosciences

**Mark Erwin, Senior Vice President, Operations**

Centric Health Finance, LLC ;Ligand Pharmaceuticals; IDEC Pharmaceuticals; Eli Lilly & Co.

**Michele L. Yelmene, Vice President, Regulatory Affairs & Quality Assurance**

Perlan Therapeutics, Genzyme Corp., Mallinckrodt

**Jose R. Hechavarria, Vice President, Manufacturing**

HechTech Pharma Consult; Bristol Myers Squibb; DuPont Pharmaceuticals

**Patrick L. Keran, J.D., General Counsel**

Isis Pharmaceuticals; Heller Ehrman; Brobeck, Phleger & Harrison

**Brandi Roberts, C.P.A., M.B.A., Vice President, Finance**

Artes Medical; Strategene; Pfizer, Inc.